{"filing":{"accession_number":"0001104659-26-092128","cik":"0001557746","ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"acrs-20260806x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806x8k.htm"},"events":[{"id":24679,"run_id":22375,"accession_number":"0001104659-26-092128","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock \"from time to time at the Company's sole discretion\" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25323,"accession_number":"0001104659-26-092128","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock \"from time to time at the Company's sole discretion\" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:36:07.157693+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25323,"accession_number":"0001104659-26-092128","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock \"from time to time at the Company's sole discretion\" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:36:07.157693+00:00","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-08-06"}]}